Charalampos Kalantzis

Dr. Charalampos Kalantzis

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Theodore G. PapaioannouTheodore G. Papaioannou
Theodore G. Papaioannou
CKCharalampos Kalantzis
Charalampos Kalantzis
EKEfstratios Katsianos
Efstratios Katsianos
Despina SanoudouDespina Sanoudou
Despina Sanoudou
MVManolis Vavuranakis
Manolis Vavuranakis
Dimitris TousoulisDimitris Tousoulis
Dimitris Tousoulis
The term “vulnerable plaque” is commonly used to refer to an atherosclerotic plaque that is prone to rupture and the formation of thrombosis, which can lead to several cardiovascular and cerebrovascular events. Coronary artery atherosclerosis has a wide variety of different phenotypes among patients who may have a substantially variable risk for plaque rupture and cardiovascular events. Mounting evidence has proposed three distinctive histopathological mechanisms: plaque rupture, plaque erosion and calcified nodules. Studies have demonstrated the characteristics of plaques with high vulnerability such as the presence of a thin fibrous cap, a necrotic lipid-rich core, abundant infiltrating macrophages and neovascularization. However, traditional coronary angiographic imaging fails to determine plaque vulnerability features, and its ability to individualize treatment strategies is limited. In recent decades, catheter-based intravascular ultrasound imaging (IVUS) modalities have been developed to identify vulnerable plaques and ultimately vulnerable patients. The aim is to individualize prediction, prevention and treatment of acute coronary events based on the identification of specific features of high-risk atherosclerotic plaques, and to identify the most appropriate interventional procedures for their treatment. In this context, the aim of this review is to discuss how personalized assessment of coronary atherosclerotic arteries can be achieved by intravascular ultrasound imaging focusing on vulnerable plaque detection.

1 November 2021 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
KKKonstantinos Kalogeras
Konstantinos Kalogeras
KNKonstantina Ntalekou
Konstantina Ntalekou
KAKonstantina Aggeli
Konstantina Aggeli
CMCarmen Moldovan
Carmen Moldovan
EKEfstratios Katsianos
Efstratios Katsianos
MVManolis Vavuranakis
Manolis Vavuranakis
Paravalvular leak (PVL) is a common complication following valve replacement, leading to heart failure and hemolysis. Transcatheter PVL closure has emerged as a reliable alternative with promising results. We quote the combined three center experience of PVL patients treated percutaneously. Consecutive patients treated percutaneously for PVL were retrospectively studied. Procedural characteristics, in-hospital and long-term clinical outcomes were assessed. Technical (successful deployment) success and clinical (NYHA and/or haemolysis improvement) success were evaluated. In total, 39 patients treated for PVL in either the aortic (12 patients) or the mitral (27 patients) position, were studied. Amplatzer Vascular Plug III was the most commonly used device among the 45 devices totally implanted. Post-procedurally, the rates of at least moderate PVL (87.5% preprocedurally vs 10.5% at discharge) and functional status, (mean NYHA class 2.8 ± 0.7 on admission vs 1.5 ± 0.8 at follow-up), were statistically significantly improved.Total population technical success rate was 89.7%, being comparable between patients treated for mitral or aortic valve PVLs (92.6% vs 83.3% respectively). Clinical success was achieved in 82.1% of patient cohort without statistical difference among those with isolated aortic or mitral PVL or among those with PVL closure indication of heart failure or hemolysis. During a mean follow-up of 33.5months, five patients died, including one peri-procedural death. This multicenter recorded experience confirms that percutaneous PVL closure can be performed with high technical and clinical success rates and limited complications leading to significant PVL reduction and functional status improvement.

1 March 2022 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
George LazarosGeorge Lazaros
George Lazaros
Konstantinos AznaouridisKonstantinos Aznaouridis
Konstantinos Aznaouridis
ELEmilia Lazarou
Emilia Lazarou
CMConstantina Masoura
Constantina Masoura
SSStergios Soulaidopoulos
Stergios Soulaidopoulos
DTDimitris Tousoulis
Dimitris Tousoulis

21 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBEvangelia Bei
Evangelia Bei
VVVasileios Voudris
Vasileios Voudris
KKKonstantinos Kalogeras
Konstantinos Kalogeras
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
IIIoannis Iakovou
Ioannis Iakovou
MVManolis Vavuranakis
Manolis Vavuranakis
A few data exist on the differences of implantable aortic valve bio-prostheses. We investigate three generations of self-expandable aortic valves in terms of the outcomes. Patients undergoing transcatheter aortic valve implantation (TAVI) were allocated into three groups according to the valve type: group A (CoreValveTM), group B (EvolutTMR) and group C (EvolutTMPRO). The implantation depth, device success, electrocardiographic parameters, need for permanent pacemaker (PPM), and paravalvular leak (PVL) were assessed. In the study, 129 patients were included. The final implantation depth did not differ among the groups (p = 0.07). CoreValveTM presented greater upward jump of the valve at release (2.88 ± 2.33 mm vs. 1.48 ± 1.09 mm and 1.71 ± 1.35 mm, for groups A, B, and C, respectively, p = 0.011). The device success (at least 98% for all groups, p = 1.00) and PVL rates (67% vs. 58%, vs. 60% for groups A, B, and C, respectively, p = 0.64) did not differ. PPM implantation within 24 h (33% vs. 19% vs. 7% for groups A, B, and C, respectively, p = 0.006) and until discharge (group A: 38% vs. group B: 19% and group C: 9%, p = 0.005) was lower in the newer generation valves. Newer generation valves present better device positioning, more predictable deployment, and fewer rates of PPM implantation. No significant difference in PVL was observed.

1 May 2021 in JACC
Verified
Journal Article
Closed access
CKCharalampos Kalantzis
Charalampos Kalantzis
MVMichael Vavuranakis
Michael Vavuranakis
KKKonstantinos Kalogeras
Konstantinos Kalogeras
EBEvangelia Bei
Evangelia Bei
CMCarmen Maria Moldovan
Carmen Maria Moldovan
MVManolis Vavuranakis
Manolis Vavuranakis

29 September 2026 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
LRLOUKIANOS RALLIDIS
LOUKIANOS RALLIDIS
DTDonatos Tsamoulis
Donatos Tsamoulis
DBDespoina-Rafailia Benetou Benetou
Despoina-Rafailia Benetou Benetou
VBVasileios Bouratzis
Vasileios Bouratzis
MPMichail Papapanou
Michail Papapanou
CVCharalambos Vlachopoulos
Charalambos Vlachopoulos